Next |
home / stock / nspr / nspr message board
Subject | By | Source | When |
---|---|---|---|
bears and bulls | Value_Investor | investorshub | 05/14/2023 5:20:14 PM |
$NSPR MomentumIts now last up | Disquisition | investorshub | 05/12/2023 8:59:56 PM |
The trading up | iluvkush | investorshub | 05/10/2023 4:00:25 PM |
Price trading last up | Disquisition | investorshub | 05/10/2023 2:10:52 AM |
Long and strong lets hope im right | Value_Investor | investorshub | 05/08/2023 2:48:36 AM |
$NSPR Good read | Value_Investor | investorshub | 05/08/2023 1:00:22 AM |
$NSPR short data if anyone is interested | Value_Investor | investorshub | 05/07/2023 11:09:51 PM |
The gaining | Value_Investor | investorshub | 05/04/2023 1:18:24 PM |
$NSPR oh yeah news for the day | TheFinalCD | investorshub | 05/03/2023 10:33:57 PM |
$NSPR MomentumIts now up | Disquisition | investorshub | 05/03/2023 11:32:31 AM |
Good read | Disquisition | investorshub | 05/02/2023 4:51:29 PM |
whytestocks: $NSPR News Article - InspireMD Announces Successful First-in-Human Procedure Utilizing | whytestocks | investorshangout | 05/01/2023 2:30:48 PM |
$NSPR great article | Value_Investor | investorshub | 04/28/2023 1:42:27 PM |
$NSPR The trading last trade up | Value_Investor | investorshub | 04/28/2023 11:45:18 AM |
Good news recently, we should start to see this one move | Value_Investor | investorshub | 04/26/2023 3:17:09 PM |
MomentumIts now up | Disquisition | investorshub | 04/26/2023 2:01:44 PM |
$NSPR Good news recently, we should start to see this one move | ClayTrader | investorshub | 04/26/2023 11:59:04 AM |
The trading | Value_Investor | investorshub | 04/25/2023 11:07:24 AM |
$NSPR here we go bulls news is here | Disquisition | investorshub | 04/24/2023 3:20:10 PM |
$NSPR Price now | Value_Investor | investorshub | 04/24/2023 12:31:58 AM |
News, Short Squeeze, Breakout and More Instantly...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protec...
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to FDA in H2 2024 U.S. commercial launch of...